Rein Therapeutics Inc. (NasdaqCM: RNTX)
Health Care · Biotechnology · US
$0.80
-2.20% today · -30.7% 1Y
Rein Therapeutics Inc. (NasdaqCM: RNTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $70.57M and employs 10 people.
Over the last twelve months the share price has lost 30.7%, trading between 0.69 and 2.18.
Tweenvest scores Rein Therapeutics Inc. across four factors: quality 26/100. Its strongest factor is quality.
RNTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $70.57M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.30
- Dividend yield
- —
- Beta (5Y)
- 1.37
- 52-week high
- $2.18
- 52-week low
- $0.69
- Avg volume (3M)
- —
- Shares outstanding
- 86.27M
- Employees
- 10
- Next earnings
- —
About Rein Therapeutics Inc.
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
- ISIN
- US00887A2042
- Founded
- 2001
- Listed since
- Jun 29, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.